Tallac Therapeutics, Inc.
Formerly Tollnine, Inc.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2020 | $62 M | No. 1 | $50 to $250 million | equity | SEC |
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Tallac Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2021).
SEC Form D · Jul 2021
The industry group it chose in its notices: Other Health Care.
SEC Form D · Jul 2021
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Tallac Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Hong Wan | Executive officer | Jul 2021 |
| Christine Brennan | Director | Jul 2021 |
| Corey Goodman | Director | Jul 2021 |
| Hong Wan | Director | Jul 2021 |
| Isaac Cheng | Director | Jul 2021 |
| Jaume Pons | Director | Jul 2021 |
| Michael Carusi | Director | Jul 2021 |
| Ran Geng | Director | Jul 2021 |